[go: up one dir, main page]

Brassard-Jollive et al., 2025 - Google Patents

3D vascularized microtumors unveil aberrant ccRCC vasculature and differential sensitivity to targeted treatments

Brassard-Jollive et al., 2025

View PDF
Document ID
8789835396039766103
Author
Brassard-Jollive N
Atlas Y
Compère C
Ardidie-Robouant C
Mailly P
El Bouchtaoui M
Lelarge V
Blot G
Josseaume N
De Oliveira S
Helary C
Leboeuf C
Cremer I
Sibony M
Bousquet G
Germain S
Muller L
Monnot C
Publication year
Publication venue
bioRxiv

External Links

Snippet

Clear cell renal cell carcinoma (ccRCC) is largely driven by Von Hippel Lindau (VHL) protein deficiency, promoting epithelial-mesenchymal transition, invasion, and hypervascularization, mediated by vascular endothelial growth factor (VEGF) signaling …
Continue reading at www.biorxiv.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells

Similar Documents

Publication Publication Date Title
Langer et al. Modeling tumor phenotypes in vitro with three-dimensional bioprinting
Han et al. Fibronectin regulates anoikis resistance via cell aggregate formation
Gener Lahav et al. Melanoma‐derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment
Kosyakova et al. Differential functional roles of fibroblasts and pericytes in the formation of tissue-engineered microvascular networks in vitro
Kuznetsov et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow–derived cells
Debnath et al. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
Shiozawa et al. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer
US11124756B2 (en) Method and apparatus for isolating invasive and metastatic cells for evaluating therapeutics and prediction of metastatic capacity
Camci‐Unal et al. Fibroblasts enhance migration of human lung cancer cells in a paper‐based coculture system
Shao et al. A novel stromal fibroblast-modulated 3D tumor spheroid model for studying tumor-stroma interaction and drug discovery
Onal et al. Breast cancer cells and macrophages in a paracrine-juxtacrine loop
Oraiopoulou et al. A 3D tumor spheroid model for the T98G Glioblastoma cell line phenotypic characterization
Landon‐Brace et al. An engineered patient‐derived tumor organoid model that can be disassembled to study cellular responses in a graded 3D microenvironment
Yamada et al. RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression
Ruiz‐Espigares et al. Evolution of metastasis study models toward metastasis‐on‐a‐chip: the ultimate model?
Yu et al. Lung cells support osteosarcoma cell migration and survival
Djirackor et al. CD166high uveal melanoma cells represent a subpopulation with enhanced migratory capacity
Peters et al. Modeling the early steps of ovarian cancer dissemination in an organotypic culture of the human peritoneal cavity
Torab et al. Three-dimensional microtumors for probing heterogeneity of invasive bladder cancer
Englund et al. Laminin matrix adhesion regulates basal mammary epithelial cell identity
Musielak et al. Biological heterogeneity of primary cancer-associated fibroblasts determines the breast cancer microenvironment
Herndon et al. The highly metastatic 4T1 breast carcinoma model possesses features of a hybrid epithelial/mesenchymal phenotype
Ayata et al. Study of in vitro capillary-like structures in psoriatic skin substitutes
Pyo et al. Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line
Charbonneau et al. Establishment of a ccRCC patient-derived chick chorioallantoic membrane model for drug testing